9th Annual Biomarkers Congress

View Profile


Grant Support

Start year End year Title Source Position
1. 2010 Characterization of MAGE-A11 for immunotherapy of prostate cancer Prostate Cancer Canada
2. 2010 Recidive biologique apres prostatectomie totale : decouverte de nouveaux marqueurs pronostics Fonds de la Recherche en Santa du Quabec Pfizer-FRSQ
3. 2010 Investigating methylation and microRNA profiles as novel prognostic markers in invasive bladder cancer Canadian Institutes of Health Research
4. 2010 Prevention of prostate cancer using micronutrients with anti-inflammatory properties Canadian Institutes of Health Research
5. 2010 Metabolic profiling of hormones and prostate cancer recurrence Canadian Institutes of Health Research
6. 2010 Identification and immunobiological characterization of non-muscle Invasive bladder cancer stem cells Cancer Research Society
7. 2009 2010 In vitro model of human primary prostate cells for the assessment of anti-inflammatory properties of chemopreventive agents. Prostate Cancer Research Foundation of Canada
8. 2009 Optimization of immunotherapy of bladder cancer: response to various non-specific immunomodulators Canadian Institutes of Health Research
9. 2006 2009 Supplement Screening for bladder cancer NCI, DHHS, NIH.
10. 2006 2009 The Sonic HEDGEHOG signalling pathway in bladder cancer: implication and therapeutic application. National Cancer Institute of Canada
11. 2008 Cancer testis antigen-based immunotherapy of bladder cancer Canadian Institutes of Health Research
12. 2005 2008 Cancer testis antigen-based immunotherapy of bladder cancer Instituts de recherche en santé du Canada
13. 2006 2007 Molecular profile of receptor tyrosine kinases in renal cell carcinomas Pfizer Canada Inc.
14. 2006 2007 Therapeutic and prognostic utilization of the HEDGEHOG pathway in localized prostate cancer Therapeutic and prognostic utilization of the HEDGEHOG pathway in localized prostate cancer
15. 2005 2007 The SLC11A1 gene in tumor surveillance and response to immunotherapy Cancer Research Society Inc.
16. 2004 2007 Prostate cancer patient sample collection and immunohistological analysis of prostate cancer antigen expression CANVAC
17. 2005 2006 Therapeutic and prognostic utilisation of the Hedgehog pathway in localized prostate cancer Canadian Prostate Cancer Research Initiative (CPCRI)
18. 2005 2006 Evaluation de limpact direct du diagnostic et du traitement du cancer de la prostate sur la consommation de services de soins specifiques Direction de la lutte contre le cancer, Ministere de la sante et des services sociaux
19. 2005 2006 Mucins for prognosis and immunotherapy of prostate cancer Prostate Cancer Research Foundation of Canada
20. 2003 2005 The NRAMP1/SLC11A1 gene in tumor surveillance and response to immunotherapy Cancer Research Society, Inc.
21. 2003 2005 Evaluation of antitumour activity of immunologically relevant prostate cancer-associated heat shock proteins Canadian Prostate Cancer Research Initiative
22. 2003 2005 Cancer testis antigens for prostate cancer chemoimmunotherapy Canadian Prostate Cancer Research Initiative
23. 2000 2005 Prostate cancer antigen discovery using a strategy combining serological and proteomic approaches CANVAC
24. 2002 2004 Molecular markers of clinically localized prostate cancer Prostate Cancer Research Foundation of Canada
25. 2000 2004 Prostate cancer antigen discovery using a strategy combining serological and proteomic approaches VRQ
26. 2002 2003 Fear of cancer recurrence in patients with prostate cancer NCIC –Canadian Prostate Cancer Research Initiative
27. 2001 2003 Cell-cycle, cellular proliferation, and apoptosis markers expression as predictive factors of outcome in renal cell carcinoma Cancer Research Society Inc.
28. 2000 2003 The Patched/Sonic Hedgehog signalling pathway in bladder carcinogenesis National Cancer Institute of Canada
29. 1999 2003 Epidemiology and clinical epidemiology of prostate cancer Medical Research Council of Canada
30. 1999 2003 Maintenance of a cell imaging core facility Medical Research Council of Canada
31. 1998 2002 A prospective study evaluating the role of p53, M344, 19A211, and T138 status in the management of transitional cell carcinoma (TCC) of the bladder before and after BCG Medical Research Council of Canada/Faulding Canada Inc.
32. 1998 2002 Antigen-based anti-bladder cancer vaccines National Cancer Institute of Canada
33. 1996 2000 Immunologic and molecular markers for diagnosis of bladder cancer National Institutes of Health
34. 1998 1999 Diet and progression of prostate cancer National Cancer Institute of Canada
35. 1998 1999 Molecular studies and therapeutic applications of superficial bladder tumor antigens National Cancer Institute of Canada
36. 1998 1999 Timing of palliative hormonal therapy and prostate cancer survival: A population based study Medical Research Council of Canada
37. 1995 1998 Molecular studies and therapeutic applications of superficial bladder tumor antigens National Cancer Institute of Canada
38. 1994 1998 Microinjection systems- equipment maintenance grant Medical Research Council of Canada
39. 1993 1998 Facteurs de pronostic et de résistance à la chimiothérapie dans le cancer du sein, du colon et de la vessie Fonds de la Recherche en Santé du Québec
40. 1994 1997 Fonds de la Recherche en Santé du Québec Reseau quebecois de recherche sur le cancer de la prostate
41. 1993 1996 Metallothionein gene expression. Bladder cancer National Institute of Health USA
42. 1993 1996 Confocal microscope -maintenance Medical Research Council of Canada
43. 1992 1996 Immunologic and molecular markers for diagnosis and prognosis of bladder cancer National Institute of Health USA
44. 1992 1995 Fonds pour la Formation de Chercheurs et l’Aide à la Recherche Programme Centres de recherche
45. 1992 1995 Molecular studies and therapeutic applications of superficial bladder tumor antigens National Cancer Institute of Canada
46. 1993 1994 Natural history of bladder cancer in relation to specific patterns of genetic and phenotypic alterations National Cancer Institute of Canada
47. 1990 1994 Influence of nutrition on occurrence and progression of prostate cancer National Cancer Institute of Canada
48. 1989 1994 Senior Scientist Award Medical Research Council of Canada
49. 1991 1993 Molecular and biological studies of tumor progression in human bladder cancer Cancer Research Society, Inc
50. 1990 1993 Epidemiological study of tumoral antigens as prognostic factors for recurrence of superficial bladder cancer National Cancer Institute of Canada
51. 1988 1992 Clinical and biological significance of bladder tumor-associated antigens. National Cancer Institute of Canada
52. 1988 1992 New markers for detection and evaluation of bladder tumors National Institute of Health, USA
53. 1989 1991 Molecular and biological studies of tumor progression in human bladder cancer Cancer Research Society, Inc.
54. 1987 1989 Cancer Research Society, Inc Cancer Research Society, Inc
55. 1987 1989 National Cancer Institute of Canada National Cancer Institute of Canada
56. 1984 1989 Scholar Medical Research Council of Canada
57. 1986 1987 Canadian Kidney Foundation Canadian Kidney Foundation
58. 1986 1987 Cancer Research Society, Inc. Cancer Research Society, Inc.
59. 1985 1987 National Cancer Institute National Cancer Institute
60. 1985 1986 Fondation Canadienne des maladies du rein Fondation Canadienne des maladies du rein
61. 1985 1986 Cancer Research Society, Inc Cancer Research Society, Inc
62. 1985 1986 Terry Fox award -additional funds National Cancer Institute of Canada
63. 1984 1986 Goup equipment grant: flowcytometry Medical Research Council of Canada
64. 1984 1985 Medical Research Council of Canada Medical Research Council of Canada
65. 1983 1985 National Cancer Institute National Cancer Institute
66. 1983 1985 Fonds detablissement de jeune chercheur FRSQ
67. 1983 1985 Scholar Canadian Urologic Association


4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.